New study suggests potent antiplatelet drug effective with low-dose aspirin
2011-06-28
(Press-News.org) When taken with higher doses of aspirin (more than 300 milligrams), the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower doses of aspirin.
The study is a secondary analysis of a clinical trial that compared the two drugs and found ticagrelor to be less effective in North America than in other countries.
Researchers suggest the aspirin dose in combination with anti-clotting medicine may alter ticagrelor's effectiveness.
The experimental antiplatelet drug ticagrelor prevented significantly more cardiovascular complications than the standard medication clopidogrel when used with low-dose aspirin, according to new research reported in the American Heart Association's Emerging Science Series webinar.
However, patients taking ticagrelor with high-dose aspirin fared worse than those taking clopidogrel, according to the researchers' new analysis of data from a clinical trial comparing the drugs. Both drugs are used to prevent potentially dangerous blood clots from forming in patients with acute coronary syndromes, including those who have suffered a heart attack.
The new analysis found that patients taking ticagrelor with less than 300 milligrams of aspirin daily were 16 percent less likely than those taking clopidogrel with low-dose aspirin to have a heart attack, stroke or to die within a year.
In the initial analysis of the data from the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor was less effective than clopidogrel in North America but not in other parts of the world. Researchers examined the PLATO data to determine why these regional differences occurred. While they could not exclude chance, they identified aspirin dose as a potential explanation.
Ticagrelor is already approved for use in some countries but still under Federal Drug Administration review in the United States.
"Patients with acute coronary syndrome have options to prevent recurrent events," said Kenneth W. Mahaffey, M.D., lead author and co-director of cardiovascular research at the Duke Clinical Research Institute, and associate professor of medicine at Duke University Medical Center. "Physicians choosing to use ticagrelor in countries where it is approved and available should consider using a low-dose of maintenance aspirin with the drug."
The study will be presented in the American Heart Association's Emerging Science Series, which will be held at 1 p.m. EDT/ 12 p.m. CDT. The series is a free online webinar presentation of cutting-edge science. The Emerging Science Series provides a new venue for presenting the latest cardiovascular scientific breakthroughs several times a year, when the discoveries are ready to be presented rather than waiting for a regularly scheduled meeting. Each study is handled in a peer-reviewed process similar to late-breaking clinical trials presented at AHA's annual Scientific Sessions.
The series will include the first presentation of data from clinical trials, basic science, key updates of previously presented trials and major bench-to-bedside breakthroughs. The webinar will be viewable from a computer or mobile phone and attendees can post questions electronically before or after the event. Presentations will be archived for on-demand viewing. For registration and information about the series visit: http://my.americanheart.org/professional/Sessions/AdditionalMeetings/EmergingScienceSeries/New-Emerging-Science-Series_UCM_424613_Article.jsp
###
Co-authors are Daniel M. Wojdyla, M.S.; Kevin Carroll, M.S.; Richard C. Becker, M.D.; Robert F. Storey, M.D., D.M.; Dominick J. Angiolillo, M.D., Ph.D.; Claes Held, M.D., Ph.D.; Christopher P. Cannon, M.D.; Stefan James, M.D., Ph.D.; Karen S. Pieper, M.S.; Jay Horrow, M.D.; Robert A. Harrington, M.D.; and Lars Wallentin, M.D., Ph.D.
Author disclosures are on the abstract. AstraZeneca funded the study.
Additional Resources:
For more on heart attack signs, prevention and treatment visit www.heart.org/heartattack.
Cardiac medications
Anti-Clotting Agents Explained
Statements and conclusions of study authors published in American Heart Association scientific meetings or presentations are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-06-28
A Clockman Vision Productions is currently packaging O.G. FUNK: TRAINING CAMP. Exec. Producer Kenny Ortega will be presenting the dance-oriented feature drama based on a story by Thomas Guzman Sanchez (urban street dancer/choreographer and film maker). An International search for cast members is now being launched. Using computer technology, anyone can audition in the comfort of their own home for this worldwide search for actors, dancers and skateboarders.
Robert Kubilos will handle directing duties on the screenplay scribed by Guzman Sanchez along with Kubilos. "Kenny ...
2011-06-28
For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients.
Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.
For the first time, human blood vessels grown in a laboratory from donor skin cells have been successfully implanted into patients, according to new research presented in the American Heart Association's ...
2011-06-28
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
A woman diagnosed with breast cancer can be tested by immunohistochemistry (IHC), a process that detects the presence of specific proteins in cancer tissue. Those who test positive ...
2011-06-28
There is a 17% greater risk of dying after a heart attack if you are treated in a hospital located in a U.S. territory—i.e. the U.S. Virgin Islands, Guam, Puerto Rico, American Samoa, and Northern Mariana Islands—rather than in a hospital in the mainland United States, according to new findings published in the Archives of Internal Medicine.
The study by Yale School of Medicine researchers shows that many U.S. citizens who call the U.S. territories home, are at a major healthcare disadvantage.
Led by Marcella Nunez-Smith, M.D., assistant professor at Yale School ...
2011-06-28
TURAN SAHINKAYA has joined the board of directors of ReputationDesigner.com, bringing more than twenty years of experience in the technology industry. Turan Sahinkaya has experience in business technology, telecom, internet and marketing and comes with the opinion that people have the right to control and protect their reputation and privacy.
Turan Sahinkaya has worked for some of the world's most recognized industry leaders, as well as several Fortune 100 companies.
Turan Sahinkaya is a graduate of University of California at Berkeley with a Bachelor's Degree in ...
2011-06-28
Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a "seeding trial" used by a pharmaceutical company to promote the drug and increase prescriptions, according to a report in the June issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
As described in the study by Yale assistant professor of medicine Joseph Ross, M.D., and his colleagues, a seeding trial is a clinical trial conducted primarily for marketing purposes and intended to promote the drug and increase prescribing by exposing ...
2011-06-28
HOUSTON – Forty-five percent of women with advanced breast cancer in the U.S. did not receive postmastectomy radiation therapy (PMRT) despite the publication of evidence-based guidelines outlining PMRT as a potentially lifesaving treatment, according to new research from The University of Texas MD Anderson Cancer Center.
The study, published in the July issue of Cancer, found that PMRT use rates for women with advanced breast cancer have remained static since 1999. According to the research, of the nearly 5,000 women diagnosed with high-risk breast cancer between 1999 ...
2011-06-28
Tutors International announces that the recent story in the international press claiming that Gwyneth Paltrow and Chris Martin have hired a private tutor from Tutors International to tutor their children is false. The story, reported initially in one of the UK tabloids was quickly spread through the national press and then featured on news networks around the world, naming Tutors International as the chosen private tutoring company, without any of the reporters in question confirming its truth with the company. For more information, visit http://www.tutors-international.com ...
2011-06-28
Most parents are unaware of the risks their teenagers face in the workplace and could do more to help them understand and prepare for those hazards, according to a new study.
Previous findings have shown that about 80 percent of teens are employed during their high school years. But the study from the University of North Carolina at Chapel Hill's Injury Prevention Research Center and North Carolina State University highlights the role parents play in helping their children get those jobs, and making good decisions about workplace safety and health.
The paper will be ...
2011-06-28
NEW YORK (June 27, 2011) – A new survey conducted by WCS scientists, supported by the U.S. Agency for International Development (USAID), reveals that large mammals, including Asiatic black bears, gray wolves, markhor goats, and leopard cats are surviving in parts of Afghanistan after years of conflict.
The field team used camera-trap surveys, transect surveys, and DNA identification of scat samples in the first wildlife update in the conflict-plagued eastern province of Nuristan since 1977. The surveys, conducted between 2006 and 2009 covering an area ...
LAST 30 PRESS RELEASES:
[Press-News.org] New study suggests potent antiplatelet drug effective with low-dose aspirin
